---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-003368"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-26T23:57:42.877231+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical Q4 2021 net income $18.7M on XIPERE milestones; CLS-AX trial advances

## Summary
- Q4 2021 license revenue $25.7M (vs $11K in Q4 2020) from $20M in XIPERE milestones; net income $18.7M ($0.31/sh) vs net loss $7.1M.
- Full year 2021 revenue $29.6M (vs $7.9M in 2020); net income $376K ($0.01/sh) vs net loss $18.2M in 2020.
- Cash $30.4M at Dec 31, 2021 plus $10M collected in Q1 2022; expects to fund operations into Q2 2023.
- CLS-AX OASIS Phase 1/2a: Cohort 3 results expected mid-2022; new Cohort 4 planned Q2 2022 to explore higher doses.
- XIPERE launched by Bausch + Lomb in U.S. in Q1 2022 for uveitic macular edema after FDA approval Oct 2021.

## SEC filing metadata
- accession: 0000950170-22-003368
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017022003368/0000950170-22-003368-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017022003368/clsd-20220310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-003368
- JSON: https://secwatch.observer/filing/0000950170-22-003368.json
- Plain text: https://secwatch.observer/filing/0000950170-22-003368.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.